The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction

Publication date: February 2020Source: IJC Heart & Vasculature, Volume 26Author(s): Xizhen Xu, Dao Wen WangAbstractBeta blockers are a recommended therapy in patients with heart failure with reduced ejection fraction(HFrEF). Beta blockers markedly and unequivocally reduce mortality in patients with heart failure with reduced ejection fraction. However, the beneficial effects of beta blockers in patients with heart failure with preserved ejection fraction(HFpEF) are not well established. In this review, we will assess the evidence basis of the recommendations for beta blockers and discuss emerging concerns about the use of beta blockers in patients with HFpEF. The available evidence for beta blockers is limited and it remains uncertain whether beta blockers have a beneficial role in the treatment of HFpEF in the absence of an alternative indication for their use.
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research